Myeloproliferative neoplasm drugs are used all over the world, especially in regions such as the United States, Singapore, and Italy. Myeloproliferative neoplasms are genetically determined abnormal cell growths that typically occur in the colon, bladder, small intestine, pancreas, or other areas of the body. While myeloproliferative neoplasms are not benign, they do pose a risk for cancer in that they can result from mutations in the genes that code for the production of the cells. The mutation in these genes can occur from many causes. Some of these causes include heredity, germicide use during childhood, chemotherapy, radiation therapy, and some viral infections. The symptoms of myeloproliferative neoplasm are similar to those of other types of cancer including breast cancer.
As with any type of cancer, there are several myeloproliferative neoplasm drugs. Some myeloproliferative neoplasm drugs involve removing the abnormal cells, whereas others attempt to destroy or remove the abnormal cells from the bone marrow. Other myeloproliferative neoplasm drugs attempt to repair the damage that has already been caused by myeloproliferative neoplasm by introducing bone marrow cells into the bloodstream. Still, other drugs are used to encourage the production of healthy bone marrow cells. In regions such as the United States, the increasing prevalence of myeloproliferative neoplasm, has increased the requirements for myeloproliferative neoplasm drugs. For instance, according to the U.S. National Cancer Institute, around 295,000 individuals are suffering from the United States.
Preventing the further development of myeloproliferative neoplasm can be achieved in many ways. These include reducing exposure to radiation and chemicals along with myeloproliferative neoplasm drugs that could damage DNA, preventing the proliferation of abnormal cells in the bone marrow, and reducing the genetic mutations that can result from exposure to radiation and chemicals. In addition, some medications that are used to prevent the development of myeloproliferative neoplasm may also help in controlling the genetic mutations that can cause disease. Some myeloproliferative neoplasm drugs are Cytarabine, Cyclophosphamide, Clafen (Cyclophosphamide), Cerubidine (Daunorubicin Hydrochloride), Azacitidine, Arsenic Trioxide, Adriamycin RDF (Doxorubicin Hydrochloride), etc.